FDA Approval Process for Medical Devices

Nov 6th, 2017Nov 7th, 2017
London, 17
GB
https://management-forum.co.uk/product/details/1022?referrer=lwmar17
Phone:2077494730
This seminar will provide a solid foundation in the approval and clearance processes for medical devices in the U.S.
Latest in Home
Minnie Cast Thumbnail (20)
Ultrasound MinnieCast, Episode 15: Wearable ultrasound making strides
August 21, 2026
True-positive PSMA-PET with positive MRI in 74-year-old male with prostate cancer (Gleason score of 4 + 5; left anterior and posterior apex positive cores). (A) Left posterior peripheral apical to midprostate hyposignal visible on transaxial MRI. (B) No definite CT correlate evident (white arrow). (C) Focal high PSMA expression detectable in left posterior mid to base with SUVmax of 12.4 on transaxial fused delayed pelvic PET/CT (yellow arrow). (D) Focal high PSMA expression found in left midgland to base of prostate on maximum-intensity-projection image (yellow arrow).
PET/CT outperforms MRI after focal therapy for prostate cancer
August 20, 2026
Nominations Are Open — 2026 Minnies
Sponsored
Nominations Are Open — 2026 Minnies
August 6, 2026
Kidney2
Thermal ablation achieves long-term survival in kidney cancer
August 20, 2026
More in Home
Ultrasound MinnieCast, Episode 15: Wearable ultrasound making strides
By Amerigo Allegretto
Geonho (Tom) Park, PhD, from Stanford Medicine shares insights from the work he and colleagues have done in wearable ultrasound.
August 21, 2026
Minnie Cast Thumbnail (20)
PET/CT outperforms MRI after focal therapy for prostate cancer
By Will Morton
No accurate noninvasive method has been validated to evaluate treatment response after focal therapy.
August 20, 2026
True-positive PSMA-PET with positive MRI in 74-year-old male with prostate cancer (Gleason score of 4 + 5; left anterior and posterior apex positive cores). (A) Left posterior peripheral apical to midprostate hyposignal visible on transaxial MRI. (B) No definite CT correlate evident (white arrow). (C) Focal high PSMA expression detectable in left posterior mid to base with SUVmax of 12.4 on transaxial fused delayed pelvic PET/CT (yellow arrow). (D) Focal high PSMA expression found in left midgland to base of prostate on maximum-intensity-projection image (yellow arrow).
Florida approves NBPAS as recognized board certification option
By AuntMinnie.com staff writers
NBPAS-certified physicians can now represent themselves as board certified in Florida physician advertising.
August 20, 2026
Florida Sign 400
Thermal ablation achieves long-term survival in kidney cancer
By Will Morton
The 10-year overall survival (OS) and cancer-specific survival (CSS) rates were 68.5% and 75.5%.
August 20, 2026
Kidney2
Most FDA-cleared AI medical devices not tested on patient outcomes
By Amerigo Allegretto
Of the 1,059 FDA-cleared devices used in radiology, three had a registered trial.
August 19, 2026
Artificial Intelligence Ai Global Communication Network 400
AI framework could improve MRI quality control in prostate cancer
By Amerigo Allegretto
The framework uses a DL model trained on low- and high-quality MR images and helped improve radiologist accuracy.
August 19, 2026
Low-quality axial T2-weighted MRI scans with gradient-weighted class activation mapping. The low-quality MRI scans (top row) show blurred structures and artifacts making zonal and capsule boundaries indistinguishable. On the same scans with gradient-weighted class activation map overlays (bottom row), red indicates regions that were most heavily weighted by the deep learning model toward the low-quality prediction.
New immuno-PET tracer shows promise in lung cancer
By Will Morton
Molecular imaging can provide whole-body visualization and quantitative assessment of PD-L1 expression.
August 18, 2026
(A) Ga-68 NK224 PET/CT maximum intensity projection image (left), axial PET/CT images (center), and axial CT images (right) in a 43-year-old female participant with lung adenocarcinoma show lesions in the right cerebellum (blue arrow), right frontal lobe (red arrow), and sternum (green arrow) with low, intermediate, and high tracer uptake, respectively. Photomicrographs (scale bar, 100 μm) with hematoxylin-eosin (H&E) staining (center bottom) and programmed death ligand 1 (PD-L1) immunohistochemical (IHC) staining (right bottom) show high PD-L1 expression in the sternal lesion (tumor proportion score ≥ 50%).
AI fracture detection device validated across three European hospitals
By Will Morton
No differences in AI performance were observed across centers, and AI assistance was associated with higher reader sensitivity.
August 18, 2026
Artificial intelligence (AI) assistance facilitates correct fracture identification in cases initially missed by human readers. A representative case is shown using anteroposterior radiographs in a 29-year-old male patient with wrist trauma (suspected nondisplaced transverse scaphoid fracture). The reader’s initial unaided assessment (top) resulted in a missed fracture, whereas with AI assistance (bottom), the fracture was correctly identified. The green box represents the fracture location as predicted by the AI tool, the blue box represents the reference standard annotation, and the red dots represent individual reader annotations.
Radiology Partners unit Mosaic petitions FDA on imaging AI regulation
By AuntMinnie.com staff writers
The petition seeks clarity on the regulation of AI vision language models used for diagnostic medical image analysis.
August 18, 2026
Artificial Intelligence Ai Medical Healthcare Tools 400
FDA issues discussion paper on GenAI medical devices
By AuntMinnie.com staff writers
The paper covers risk assessment, pre-market evaluation, and considerations around foundation models and agentic AI systems.
August 18, 2026
Fda Button 400
CT for breast radiotherapy detects ischemic heart disease risk
By Will Morton
As survival after early-stage breast cancer improves, cardiovascular disease has emerged as an increasingly prominent competing risk in older women.
August 17, 2026
Heart 1
MWA may have long-term benefits for renal cell cancer patients
By Amerigo Allegretto
MWA with CT or CEUS guidance leads to "excellent" 10-year survival rates and with minimal complications.
August 17, 2026
Kidneys 400
Page 1 of 245
Next Page